| All Releases |
|---|
 |
Progenics Presents Novel Multiplex PI3-Kinase Inhibitors at American Association for Cancer Research Conference on Protein Translation and Cancer
Feb 4, 2010
|
15.8 KB
|
| |
TARRYTOWN, N.Y. & CORONADO, Calif., Feb 04, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
presentation of preclinical data on a series of novel compounds that
simultaneously blocked two critical pathways involved in the growth and
survival of cancer cells. The compounds were ident...
|
|
|
CORRECTING and REPLACING Progenics Announces Third Quarter 2009 Financial Results
Nov 9, 2009
|
24.5 KB
|
| |
TARRYTOWN, N.Y., Nov 09, 2009 (BUSINESS WIRE) -- In the October Highlights section, the third sentence in the second
bullet should read xxx Significantly more patients on study drug
experienced laxation within two and four hours compared to those on
placebo (33% versus 0%, [p<0.05] and 39% versus 7%, [p<0.05],
respec...
|
|
|
Progenics Announces Third Quarter 2009 Financial Results
Nov 9, 2009
|
23.3 KB
|
| |
TARRYTOWN, N.Y., Nov 09, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the third quarter and nine months ended
September 30, 2009.
Financial ResultsNet loss for the third quarter of 2009 was $13.0 million or $0.41, basic
and diluted, per share, compared ...
|
|
|
Progenics Regains Worldwide Rights to RELISTOR Franchise
Oct 14, 2009
|
22.6 KB
|
| |
TARRYTOWN, N.Y., Oct 14, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it
has entered into an agreement with Wyeth Pharmaceuticals, a division of
Wyeth (NYSE: WYE) under which Progenics is regaining all worldwide
rights to the RELISTOR(R) franchise from Wyeth Pharmaceuticals,
...
|
|
|
Progenics Announces Promotion of Mark R. Baker to President and Appoints Him to Board of Directors
Sep 16, 2009
|
13.8 KB
|
| |
TARRYTOWN, N.Y., Sep 16, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
promotion of Mark R. Baker to the newly created position of President.
Mr. Baker was also appointed to the Board of Directors. He will continue
to report to Paul J. Maddon, M.D., Ph.D., Progenics' Founder, Chie...
|
|
|
Progenics Announces Second Quarter 2009 Financial Results
Aug 6, 2009
|
19.3 KB
|
| |
TARRYTOWN, N.Y., Aug 06, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the quarter and six months ended June 30, 2009.
Financial ResultsNet loss for the second quarter of 2009 was $15.2 million or $0.49,
basic and diluted, per share, compared to $2.4 million or ...
|
|
|
New Delivery System for RELISTOR in Pre-Filled Syringes Submitted for U.S. and European Marketing Approval
Aug 4, 2009
|
19.2 KB
|
| |
TARRYTOWN, N.Y. & COLLEGEVILLE, Pa., Aug 04, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Wyeth
Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced
submission of a supplemental New Drug Application (sNDA) to the United
States (U.S.) Food and Drug Administration (FDA) and an Extensi...
|
|
|
Progenics Announces Initiation of RELISTOR Clinical Trials in Japan by Ono Pharmaceutical
Jun 8, 2009
|
16.6 KB
|
| |
TARRYTOWN, N.Y., Jun 08, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that its
collaborator, Ono Pharmaceutical Co., Ltd., Osaka, Japan (OSE-TYO: 4528)
has begun clinical testing in Japan of RELISTOR(R)
(methylnaltrexone bromide) subcutaneous injection, the first-in-class
med...
|
|
|
Progenics Provides Update on Hepatitis C Program
Jun 8, 2009
|
13.1 KB
|
| |
TARRYTOWN, N.Y., Jun 08, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
discontinuation of development for PRO 206, a pre-clinical compound for
the treatment of hepatitis C virus (HCV) infection. The decision was
made as part of a portfolio review, and is in line with the Company's...
|
|
|
Progenics Announces First Quarter Financial Results
May 11, 2009
|
21.3 KB
|
| |
TARRYTOWN, N.Y., May 11, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the quarter ended March 31, 2009.
First Quarter Financial ResultsNet loss was $1.8 million or $0.06, basic and diluted, per share,
compared to $15.5 million or $0.52, basic and diluted, per s...
|
|
|
Phase 3 Clinical Study of RELISTOR Presented at American Pain Society Meeting Showed Positive Activity for the Treatment of Opioid-Induced Constipation in Chronic,Non-Cancer Pain Patients
May 7, 2009
|
22.7 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., May 07, 2009 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced results from the
one-month, double-blind portion of a phase 3 trial of RELISTOR(R)
(methylnaltrexone bromide) subcutaneous injection t...
|
|
|
Progenics Pharmaceuticals Reports Fourth Quarter and Year-End Results and Corporate Update
Mar 13, 2009
|
23.6 KB
|
| |
TARRYTOWN, N.Y., Mar 13, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the fourth quarter and year ended December 31,
2008.
Revenues for the fourth quarter totaled $6.8 million, compared to $15.5
million for the same period of 2007. For the year ended De...
|
|
|
Progenics Selects Subcutaneous Form of PRO 140, A Novel HIV Antibody Therapy, For Further Development
Feb 10, 2009
|
75.3 KB
|
| |
Montreal, Quebec and Tarrytown, NY - February 10, 2009 - Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it has selected for further development the subcutaneous form of PRO 140 for the treatment of HIV infection. The decision follows positive results from a recently completed phase 2 clinical trial as well as feedbac...
|
|
|
Progenics Appoints Peter J. Crowley as Independent Board Member
Feb 4, 2009
|
13.2 KB
|
| |
TARRYTOWN, N.Y., Feb 04, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
appointment of Peter J. Crowley to its Board of Directors as an
independent director. A senior healthcare investment banker with over 20
years' experience in the industry, Mr. Crowley will also serve on the
...
|
|
|
Announcement by Progenics Pharmaceuticals under Nasdaq Marketplace Rules
Dec 11, 2008
|
12.5 KB
|
| |
TARRYTOWN, N.Y., Dec 11, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that it
has received a Nasdaq Staff Deficiency Letter indicating that it fails
to comply with Nasdaq's audit committee requirements. As a result of Mr.
Paul F. Jacobson's previously-announced resignation from the C...
|
|
|
Wyeth and Progenics Announce Positive Outcome of Phase 3 Clinical Study of Subcutaneous RELISTOR for Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain
Nov 26, 2008
|
19.7 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., Nov 26, 2008 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that a phase 3
clinical study investigating RELISTOR(R) (methylnaltrexone
bromide) subcutaneous injection to treat opioid-induced cons...
|
|
|
Progenics Announces Wyeth Has Received Relistor Approval in Australia
Nov 17, 2008
|
14.3 KB
|
| |
Tarrytown, NY, November 17, 2008 -Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced the Therapeutic Goods Administration (TGA) division of the Australian Government has approved the registration of RELISTOR® (methylnaltrexone bromide 12mg/0.6ml solution for injection) for the treatment of opioid-induced constipation (OIC...
|
|
|
Progenics Reports Third Quarter 2008 Financial Results and Corporate Updates
Nov 10, 2008
|
20.1 KB
|
| |
TARRYTOWN, N.Y., Nov 10, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the third quarter and nine months ended September 30, 2008.
Revenues for the third quarter totaled $17.5 million, compared to $17.0 million for the same period of 2007. For the nine months ended September...
|
|
|
Progenics Selects Small-Molecule Hepatitis C Drug Candidate for Clinical Development
Nov 4, 2008
|
14.7 KB
|
| |
SAN FRANCISCO & TARRYTOWN, N.Y., Nov 04, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the selection of a proprietary small-molecule drug candidate, designated PRO 206, for clinical development as a treatment of hepatitis C virus (HCV) infection. Pre-clinical results supporting the development of PRO 206 wer...
|
|
|
Progenics Reports Positive Interim Phase 2 Results for Two Dosage Forms 0f Novel HIV Therapy PRO 140
Oct 26, 2008
|
227.1 KB
|
| |
Washington, DC and Tarrytown, NY - October 26, 2008 - Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced positive interim results from two separate phase 2 clinical trials of PRO 140 for the treatment of HIV infection. Both intravenous and subcutaneous forms of PRO 140, a novel viral-entry inhibitor, exhibited potent and prolo...
|
|
|
